Sulfonylurea News and Research

RSS
Long-term linagliptin effective treatment for Type 2 diabetes

Long-term linagliptin effective treatment for Type 2 diabetes

Alogliptin adds benefits to diabetes monotherapy

Alogliptin adds benefits to diabetes monotherapy

Liraglutide efficacy in Japanese patients “easy” to predict

Liraglutide efficacy in Japanese patients “easy” to predict

Three widely used diabetes medications associated with greater risk of death

Three widely used diabetes medications associated with greater risk of death

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

GLP-1 receptor agonist boosts glycemic control in Asian patients

GLP-1 receptor agonist boosts glycemic control in Asian patients

Linagliptin safe and effective for African American patients with type 2 diabetes

Linagliptin safe and effective for African American patients with type 2 diabetes

European Commission grants marketing authorization for use of BYETTA with basal insulin

European Commission grants marketing authorization for use of BYETTA with basal insulin

Lilly, Boehringer Ingelheim announce availability of Jentadueto tablets

Lilly, Boehringer Ingelheim announce availability of Jentadueto tablets

The Lancet publishes Takeda's TAK-875 Phase 2 data on type 2 diabetes

The Lancet publishes Takeda's TAK-875 Phase 2 data on type 2 diabetes

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Merck receives FDA approval for JANUMET XR to treat type 2 diabetes

Merck receives FDA approval for JANUMET XR to treat type 2 diabetes

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Linagliptin does not offer added benefit for adults with type 2 diabetes

Linagliptin does not offer added benefit for adults with type 2 diabetes

Amylin and Lilly terminate exenatide alliance, resolve litigation

Amylin and Lilly terminate exenatide alliance, resolve litigation

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Lilly, Boehringer Ingelheim to present latest data from diabetes portfolio at 47th EASD meeting

Lilly, Boehringer Ingelheim to present latest data from diabetes portfolio at 47th EASD meeting

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes